Panelists discuss the BTK inhibitor ibrutinib, which has gained approval as a treatment for patients with chronic lymphocytic leukemia and mantle cell lymphoma.
To view more from this discussion, visit [ Ссылка ]
Ещё видео!
Panelists discuss the BTK inhibitor ibrutinib, which has gained approval as a treatment for patients with chronic lymphocytic leukemia and mantle cell lymphoma.
To view more from this discussion, visit [ Ссылка ]